Blog
Pharma's Kodak moment
The demise of the storied photography firm shows how the links in a value chain can become decoupled under one's feet. What does this mean for Pharma?
Disclosure of trial results - a continuing saga
It's time to bring data to the mud-slinging debate over disclosure of clinical trial results. A recent article provides a good starting point.
New drugs less effective than old ones? Not so fast (continued)
A recently-published screed about pharma R&D plumbs new depths in pharmascolding. Let's see if it holds up to scrutiny. (Want to take a wild guess?)
How to cure cancer? A review of "The Truth in Small Doses" by Clifton Leaf
Leaf's book is a powerful call to action to focus on the "C" word in oncology - "cure".
Why oncology companies should care about drug adherence
Many companies think adherence isn't an issue in cancer care. They're wrong.
New drugs less effective than old ones? Not so fast...
Q: Are we really making worse drugs now than we used to, as suggested by a recent high-profile news article? A: No. And I'll explain why.
Taking on the "pharmascolds"
It's time to stop demonizing research interactions between physicians and Pharma, and start fighting rhetorical fire with hard data.
Performance-based pricing, part 2
A few more thoughts on drug pricing, following up on a prior post.
Performance-based drug pricing and the "Wanamaker problem"
We have tools available today to improve the drug pricing system. Let's start using them.
Oncology combinations β four key elements to biopharma success
If Pharma companies want to succeed in cancer R&D, they need to get better at handling combinations. Here are some places to start.